NCT00004901 is a Phase 1/Phase 2 clinical trial of ethynyluracil in Head and Neck Cancer, sponsored by Robert H. Lurie Cancer Center.

Who is sponsoring NCT00004901?

NCT00004901 is sponsored by Robert H. Lurie Cancer Center.

What drugs are being tested in NCT00004901?

Interventions in NCT00004901: ethynyluracil, fluorouracil, hydroxyurea, radiation therapy.

What condition does NCT00004901 study?

NCT00004901 studies Head and Neck Cancer.

Is NCT00004901 still recruiting?

NCT00004901 is currently completed. Last updated 25 June 2013.

Last reviewed 2013-06-25 · How we verify

NCT00004901

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer

Completed Phase 1/Phase 2 Last updated 25 June 2013

What this trial tests

Phase 1/Phase 2 trial testing ethynyluracil in Head and Neck Cancer. Completed in 1 July 2004.

Timeline

1 October 1999

1 July 2004

Quick facts

Lead sponsor	Robert H. Lurie Cancer Center
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 October 1999
Estimated completion	1 July 2004
Sites	2 locations across United States

Drugs / interventions tested

ethynyluracil — full drug profile →
fluorouracil — full drug profile →
hydroxyurea — full drug profile →
radiation therapy — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Robert H. Lurie Cancer Center

Who can join

18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have advanced mouth cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00004901 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Robert H. Lurie Cancer Center
Last refreshed: 25 June 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00004901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing